Weaver C. Barksdale & Associates’s Bio-Rad Laboratories Class A BIO Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$11K	Sell	46 -4	-8%	-$969	0.01%	260
2017 Q3	$11K	Hold	50	–	–	0.01%	250
2017 Q2	$11K	Sell	50 -16	-24%	-$3.49K	0.01%	244
2017 Q1	$13K	Hold	66	–	–	0.02%	215
2016 Q4	$12K	Buy	66 +5	+8%	+$852	0.02%	241
2016 Q3	$10K	Sell	61 -5	-8%	-$759	0.02%	255
2016 Q2	$9K	Hold	66	–	–	0.02%	257
2016 Q1	$9K	Hold	66	–	–	0.01%	279
2015 Q4	$9K	Hold	66	–	–	0.01%	271
2015 Q3	$9K	Hold	66	–	–	0.01%	268
2015 Q2	$10K	Sell	66 -12	-15%	-$1.72K	0.01%	275
2015 Q1	$11K	Hold	78	–	–	0.01%	257
2014 Q4	$9K	Sell	78 -7	-8%	-$806	0.01%	282
2014 Q3	$10K	Hold	85	–	–	0.01%	258
2014 Q2	$10K	Buy	85 +10	+13%	+$1.22K	0.01%	270
2014 Q1	$10K	Hold	75	–	–	0.01%	255
2013 Q4	$9K	Hold	75	–	–	0.01%	291
2013 Q3	$9K	Hold	75	–	–	0.01%	280
2013 Q2	$8K	Buy	+75	New	+$8.8K	0.01%	299

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HCM

Hitchwood Capital Management New York $184M AUM 3.18% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Weaver C. Barksdale & Associates's BIO Position: Q4 2017 in Review

Weaver C. Barksdale & Associates reduced its Bio-Rad Laboratories Class A (BIO) stake by 8% in Q4 2017, selling an estimated $969 and leaving 46 shares worth $11K. The position accounts for 0.01% of the portfolio, ranked #260.

Weaver C. Barksdale & Associates first reported a position in BIO in Q2 2013 and has held it in 19 quarters since. The position peaked at $13K in Q1 2017. 302 funds tracked by Wall St. Rank hold BIO as of Q4 2017.

Weaver C. Barksdale & Associates held 46 shares of Bio-Rad Laboratories Class A worth $11K as of Q4 2017.
Weaver C. Barksdale & Associates sold 4 Bio-Rad Laboratories Class A shares in Q4 2017, an estimated $969.
Bio-Rad Laboratories Class A made up 0.01% of Weaver C. Barksdale & Associates's portfolio in Q4 2017, its #260 holding.
Weaver C. Barksdale & Associates first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 19 quarters since.
Weaver C. Barksdale & Associates's Bio-Rad Laboratories Class A position peaked at $13K in Q1 2017.
302 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2017.

Based on Weaver C. Barksdale & Associates's 13F filing for Q4 2017, filed 10 Jan 2018.